March 28, 2022 -- Kirilys Therapeutics, a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, has announced that it completed a seed financing led by Lightspeed Venture Partners.
Kirilys Therapeutics also said that it licensed KRLS-017, its lead compound, from Ube Industries. The company said the financing round will enable Kirilys to complete all activities through the Investigational New Drug filing of KRLS-017, as well as preparatory work for the phase I clinical development program.
KRLS-017, a reversible small molecule inhibitor of cyclin dependent kinase 7 (CDK7), showed selectivity and antitumor efficacy along with very favorable properties for an oral drug, Kirily's said.
Finally, the company reported that it also completed a partnership agreement with D2G Oncology, which uses genetically defined animal tumor models to reveal relationships between cancer genotypes and drug efficacy.
Copyright © 2022 scienceboard.net